← All trials
NCT06578247
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 30, 2024
- Primary completion
- Jun 26, 2030
- Completion date
- Jun 26, 2030
- First posted
- Aug 29, 2024
- Last posted
- Oct 16, 2024
- Enrollment
- 700
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Daiichi SankyoLead sponsor
- Daiichi SankyoOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.